Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors

G. Varuni Kondagunta, Jennifer Bacik, Lawrence Schwartz, Joel Sheinfeld, Dean Bajorin, Jacqueline Vuky, Stephanie Marion, Madhu Mazumdar, George J. Bosl, Robert J. Motzer

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Fourteen patients with cisplatin-refractory germ cell tumors (GCT) were treated with temozolomide on a phase II trial. Temozolomide was given orally at 150 mg/m2/day on days 1-5. The cycle length was 28 days. No patient experienced a grade 3 or 4 toxicity, and none of the 14 evaluable patients achieved a complete or partial response. Temozolomide is not efficacious in the treatment of cisplatin-refractory GCT patients.

Original languageEnglish (US)
Pages (from-to)177-179
Number of pages3
JournalInvestigational New Drugs
Volume22
Issue number2
DOIs
StatePublished - Apr 2004
Externally publishedYes

Fingerprint

temozolomide
Germ Cell and Embryonal Neoplasms
Cisplatin

Keywords

  • Cisplatin-refractory
  • Germ cell tumor
  • Nonseminoma
  • Phase II
  • Temozolomide

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Kondagunta, G. V., Bacik, J., Schwartz, L., Sheinfeld, J., Bajorin, D., Vuky, J., ... Motzer, R. J. (2004). Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors. Investigational New Drugs, 22(2), 177-179. https://doi.org/10.1023/B:DRUG.0000011794.21608.59

Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors. / Kondagunta, G. Varuni; Bacik, Jennifer; Schwartz, Lawrence; Sheinfeld, Joel; Bajorin, Dean; Vuky, Jacqueline; Marion, Stephanie; Mazumdar, Madhu; Bosl, George J.; Motzer, Robert J.

In: Investigational New Drugs, Vol. 22, No. 2, 04.2004, p. 177-179.

Research output: Contribution to journalArticle

Kondagunta, GV, Bacik, J, Schwartz, L, Sheinfeld, J, Bajorin, D, Vuky, J, Marion, S, Mazumdar, M, Bosl, GJ & Motzer, RJ 2004, 'Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors', Investigational New Drugs, vol. 22, no. 2, pp. 177-179. https://doi.org/10.1023/B:DRUG.0000011794.21608.59
Kondagunta, G. Varuni ; Bacik, Jennifer ; Schwartz, Lawrence ; Sheinfeld, Joel ; Bajorin, Dean ; Vuky, Jacqueline ; Marion, Stephanie ; Mazumdar, Madhu ; Bosl, George J. ; Motzer, Robert J. / Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors. In: Investigational New Drugs. 2004 ; Vol. 22, No. 2. pp. 177-179.
@article{d43b8f869048447da6816a8e429e51ed,
title = "Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors",
abstract = "Fourteen patients with cisplatin-refractory germ cell tumors (GCT) were treated with temozolomide on a phase II trial. Temozolomide was given orally at 150 mg/m2/day on days 1-5. The cycle length was 28 days. No patient experienced a grade 3 or 4 toxicity, and none of the 14 evaluable patients achieved a complete or partial response. Temozolomide is not efficacious in the treatment of cisplatin-refractory GCT patients.",
keywords = "Cisplatin-refractory, Germ cell tumor, Nonseminoma, Phase II, Temozolomide",
author = "Kondagunta, {G. Varuni} and Jennifer Bacik and Lawrence Schwartz and Joel Sheinfeld and Dean Bajorin and Jacqueline Vuky and Stephanie Marion and Madhu Mazumdar and Bosl, {George J.} and Motzer, {Robert J.}",
year = "2004",
month = "4",
doi = "10.1023/B:DRUG.0000011794.21608.59",
language = "English (US)",
volume = "22",
pages = "177--179",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors

AU - Kondagunta, G. Varuni

AU - Bacik, Jennifer

AU - Schwartz, Lawrence

AU - Sheinfeld, Joel

AU - Bajorin, Dean

AU - Vuky, Jacqueline

AU - Marion, Stephanie

AU - Mazumdar, Madhu

AU - Bosl, George J.

AU - Motzer, Robert J.

PY - 2004/4

Y1 - 2004/4

N2 - Fourteen patients with cisplatin-refractory germ cell tumors (GCT) were treated with temozolomide on a phase II trial. Temozolomide was given orally at 150 mg/m2/day on days 1-5. The cycle length was 28 days. No patient experienced a grade 3 or 4 toxicity, and none of the 14 evaluable patients achieved a complete or partial response. Temozolomide is not efficacious in the treatment of cisplatin-refractory GCT patients.

AB - Fourteen patients with cisplatin-refractory germ cell tumors (GCT) were treated with temozolomide on a phase II trial. Temozolomide was given orally at 150 mg/m2/day on days 1-5. The cycle length was 28 days. No patient experienced a grade 3 or 4 toxicity, and none of the 14 evaluable patients achieved a complete or partial response. Temozolomide is not efficacious in the treatment of cisplatin-refractory GCT patients.

KW - Cisplatin-refractory

KW - Germ cell tumor

KW - Nonseminoma

KW - Phase II

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=10744223010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744223010&partnerID=8YFLogxK

U2 - 10.1023/B:DRUG.0000011794.21608.59

DO - 10.1023/B:DRUG.0000011794.21608.59

M3 - Article

C2 - 14739666

AN - SCOPUS:10744223010

VL - 22

SP - 177

EP - 179

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 2

ER -